Celldex Therapeutics (CLDX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$583.2 million.
- Celldex Therapeutics' Enterprise Value rose 2285.4% to -$583.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$583.2 million, marking a year-over-year increase of 2285.4%. This contributed to the annual value of -$725.3 million for FY2024, which is 7121.92% down from last year.
- Latest data reveals that Celldex Therapeutics reported Enterprise Value of -$583.2 million as of Q3 2025, which was up 2285.4% from -$630.3 million recorded in Q2 2025.
- Celldex Therapeutics' Enterprise Value's 5-year high stood at -$164.0 million during Q2 2021, with a 5-year trough of -$823.8 million in Q1 2024.
- Moreover, its 5-year median value for Enterprise Value was -$408.2 million (2021), whereas its average is -$459.0 million.
- As far as peak fluctuations go, Celldex Therapeutics' Enterprise Value plummeted by 22776.7% in 2021, and later soared by 2918.02% in 2023.
- Quarter analysis of 5 years shows Celldex Therapeutics' Enterprise Value stood at -$408.2 million in 2021, then increased by 25.3% to -$305.0 million in 2022, then plummeted by 38.91% to -$423.6 million in 2023, then tumbled by 71.22% to -$725.3 million in 2024, then grew by 19.59% to -$583.2 million in 2025.
- Its last three reported values are -$583.2 million in Q3 2025, -$630.3 million for Q2 2025, and -$673.3 million during Q1 2025.